Alessandra Pulvirenti, Nitya Raj1, Sara Cingarlini2, Antonio Pea3, Laura H Tang4, Claudio Luchini5, Joanne F Chou6, Elisabetta Grego2, Ioana Marinova4, Marinela Capanu6, Luca Landoni3, Aldo Scarpa5, Peter J Allen7, David S Klimstra4, Diane L Reidy-Lagunes1. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Oncology, University of Verona Hospital Trust, Verona, Italy. 3. Unit of General and Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Diagnostics and Public Health, Section of Pathology, University of Verona Hospital Trust, Verona, Italy. 6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 7. Department of Surgery, Hepatopancreatobiliary Service, Duke University School of Medicine, Durham, NC.
Abstract
OBJECTIVES: Pancreatic neuroendocrine neoplasms include well-differentiated tumors (PanNETs) and poorly differentiated carcinomas (PanNECs). Previous reports suggested a role for platinum-based therapy largely in PanNEC. We sought to investigate the role of platinum-based therapy in pancreatic neuroendocrine neoplasms regardless of tumor grade and differentiation. METHODS: Patients with pancreatic neuroendocrine neoplasms treated with platinum-based therapy at Memorial Sloan Kettering (1994-2016) and Verona University Hospital (2008-2016) were retrospectively identified. Response to treatment by RECIST v1.1, overall survival, and progression-free survival were defined. Among patients with available tissue, DAXX, ATRX, Rb, and p53 expression was evaluated to support the histologic grade of differentiation. RESULTS: Fifty PanNETs, 29 PanNECs, and 22 high-grade tumors with undeterminable differentiation were included. No patients achieved complete response. Overall rate of partial response was 31%, 41% for PanNEC, and 20% for PanNETs. Among PanNETs, partial response was achieved in 33% of G1 (2/6), 10% of G2 (2/19), and 24% of G3 (6/25) tumors. Median overall survival was 29.3 months for PanNETs and 10.9 months for PanNEC (P < 0.001). There was no significant difference in median progression-free survival (P = 0.2). CONCLUSIONS: Platinum-based therapies demonstrated increased activity in PanNEC; however, promising efficacy was also observed in PanNETs, irrespective of grade.
OBJECTIVES: Pancreatic neuroendocrine neoplasms include well-differentiated tumors (PanNETs) and poorly differentiated carcinomas (PanNECs). Previous reports suggested a role for platinum-based therapy largely in PanNEC. We sought to investigate the role of platinum-based therapy in pancreatic neuroendocrine neoplasms regardless of tumor grade and differentiation. METHODS: Patients with pancreatic neuroendocrine neoplasms treated with platinum-based therapy at Memorial Sloan Kettering (1994-2016) and Verona University Hospital (2008-2016) were retrospectively identified. Response to treatment by RECIST v1.1, overall survival, and progression-free survival were defined. Among patients with available tissue, DAXX, ATRX, Rb, and p53 expression was evaluated to support the histologic grade of differentiation. RESULTS: Fifty PanNETs, 29 PanNECs, and 22 high-grade tumors with undeterminable differentiation were included. No patients achieved complete response. Overall rate of partial response was 31%, 41% for PanNEC, and 20% for PanNETs. Among PanNETs, partial response was achieved in 33% of G1 (2/6), 10% of G2 (2/19), and 24% of G3 (6/25) tumors. Median overall survival was 29.3 months for PanNETs and 10.9 months for PanNEC (P < 0.001). There was no significant difference in median progression-free survival (P = 0.2). CONCLUSIONS: Platinum-based therapies demonstrated increased activity in PanNEC; however, promising efficacy was also observed in PanNETs, irrespective of grade.
Authors: Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue Journal: Am J Surg Pathol Date: 2012-02 Impact factor: 6.394
Authors: R Garcia-Carbonero; H Sorbye; E Baudin; E Raymond; B Wiedenmann; B Niederle; E Sedlackova; C Toumpanakis; M Anlauf; J B Cwikla; M Caplin; D O'Toole; A Perren Journal: Neuroendocrinology Date: 2016-01-05 Impact factor: 4.914
Authors: Olca Basturk; Laura Tang; Ralph H Hruban; Volkan Adsay; Zhaohai Yang; Alyssa M Krasinskas; Efsevia Vakiani; Stefano La Rosa; Kee-Taek Jang; Wendy L Frankel; Xiuli Liu; Lizhi Zhang; Thomas J Giordano; Andrew M Bellizzi; Jey-Hsin Chen; Chanjuan Shi; Peter Allen; Diane L Reidy; Christopher L Wolfgang; Burcu Saka; Neda Rezaee; Vikram Deshpande; David S Klimstra Journal: Am J Surg Pathol Date: 2014-04 Impact factor: 6.394
Authors: H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge Journal: Ann Oncol Date: 2012-09-11 Impact factor: 32.976
Authors: Alessandra Pulvirenti; Ammar A Javed; Luca Landoni; Nigel B Jamieson; Joanne F Chou; Marco Miotto; Jin He; Mithat Gonen; Antonio Pea; Laura H Tang; Chiara Nessi; Sara Cingarlini; Michael I D'Angelica; Anthony J Gill; T Peter Kingham; Aldo Scarpa; Matthew J Weiss; Vinod P Balachandran; Jaswinder S Samra; John L Cameron; William R Jarnagin; Roberto Salvia; Christopher L Wolfgang; Peter J Allen; Claudio Bassiy Journal: Ann Surg Date: 2021-12-01 Impact factor: 13.787
Authors: Antonio Pea; Jun Yu; Luigi Marchionni; Michael Noe; Claudio Luchini; Alessandra Pulvirenti; Roeland F de Wilde; Lodewijk A Brosens; Neda Rezaee; Ammar Javed; Peter Chianchiano; Stefano Gobbo; Paolo Regi; Roberto Salvia; Claudio Bassi; Jin He; Matthew J Weiss; John L Cameron; G Johan A Offerhaus; Ralph H Hruban; Rita T Lawlor; Aldo Scarpa; Christopher M Heaphy; Laura D Wood; Christopher L Wolfgang Journal: Ann Surg Date: 2020-03 Impact factor: 13.787
Authors: Pablo Remón-Ruiz; Eva Venegas-Moreno; Elena Dios-Fuentes; Juan Manuel Canelo Moreno; Ignacio Fernandez Peña; Miriam Alonso Garcia; Miguel Angel Japón-Rodriguez; Florinda Roldán; Elena Fajardo; Ariel Kaen; Eugenio Cardenas Ruiz-Valdepeñas; David Cano; Alfonso Soto-Moreno Journal: Front Endocrinol (Lausanne) Date: 2021-12-21 Impact factor: 5.555
Authors: Elettra Merola; Andrea Michielan; Umberto Rozzanigo; Marco Erini; Sandro Sferrazza; Stefano Marcucci; Chiara Sartori; Chiara Trentin; Giovanni de Pretis; Franca Chierichetti Journal: World J Gastrointest Surg Date: 2022-02-27